Rituximab in treatment of anti-GBM antibody glomerulonephritis-Reference-Cited by-同舟云学术

Rituximab in treatment of anti-GBM antibody glomerulonephritis

Published:2019-11 Issue:44 Volume:98 Page:e17801
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Uematsu-Uchida Mayu,Ohira Takehiro,Tomita Shigeki,Satonaka Hiroshi,Tojo Akihiro,Ishimitsu Toshihiko

Funder

a research donation from Dr. Naohiko Kobayashi, Director of Kobayashi Medical Clinic, in Yasuzuka, Mibu

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference21 articles.

1. Goodpasture antigen: expression of the full-length alpha3 (IV) chain of collagen IV and localization of epitopes exclusively to the noncollagenous domain;Leinonen;Kidney Int,1999

2. The molecular basis of Goodpasture and Alport syndromes: beacons for the discovery of the collagen IV family;Hudson;J Am Soc Nephrol,2004

3. Identification of the alpha 3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and Goodpasture syndrome;Kalluri;J Am Soc Nephrol,1995

4. Presentation of the Goodpasture autoantigen to CD4 T cells is influenced more by processing constraints than by HLA class II peptide binding preferences;Phelps;J Biol Chem,1998

5. Presentation of the Goodpasture autoantigen requires proteolytic unlocking steps that destroy prominent T cell epitopes;Zou;J Am Soc Nephrol,2007

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recomendaciones para el diagnóstico y tratamiento de las vasculitis asociadas a anticuerpos anticitoplasma de neutrófilo;Nefrología;2024-08

2. A Unique Case of Goodpasture’s Syndrome-Induced Cardiorenal Syndrome;Cureus;2024-07-10

3. The Immunobiological Agents for Treatment of Antiglomerular Basement Membrane Disease;Medicina;2023-11-16

4. Anti-topoisomerase 1 Antibody Level Changes after B Cell Depletion Therapy in Systemic Sclerosis;Doklady Biochemistry and Biophysics;2023-08

5. Contemporary Monoclonal Antibody Utilization in Glomerular Diseases;Mayo Clinic Proceedings: Innovations, Quality & Outcomes;2023-08